We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01935414
Recruitment Status : Recruiting
First Posted : September 5, 2013
Last Update Posted : February 7, 2018
Information provided by (Responsible Party):
Firstkind Ltd

Brief Summary:
This study hypothesises that the geko™ device is more efficient than TEDS in preventing the formation of symptomatic/asymptomatic Deep Vein Thrombosis (DVTs), post-surgery.

Condition or disease Intervention/treatment
Deep Vein Thrombosis Device: geko™ post-surgery for 48hrs then 4hrs/day until discharge. Device: TEDS post-surgery for 48hrs then 4hrs/day until discharge.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicentre Randomised Controlled Trial Comparing the Incidence of Asymptomatic and Symptomatic Deep Vein Thrombosis Between the gekoTM Device and Thromboembolism Deterrent Stockings in Patients Recovering From Total Hip Replacement Surgery
Study Start Date : August 2013
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: geko™
geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
Device: geko™ post-surgery for 48hrs then 4hrs/day until discharge.
Active Comparator: TEDS stockings
TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
Device: TEDS post-surgery for 48hrs then 4hrs/day until discharge.

Primary Outcome Measures :
  1. Presence of asymptomatic DVT assessed by Duplex Ultrasound [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Aged 18 years of age and over
  2. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders).
  3. Has not used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the ten (10) days preceding enrolment.
  4. Able to understand the Patient Information Sheet and willing to sign the written Informed Consent Form.
  5. Able and willing to follow the protocol requirements.

Exclusion Criteria:

  1. Are requiring hip revision surgery
  2. History or signs of previous deep or superficial vein thrombosis/pulmonary embolism.
  3. Evidence of asymptomatic DVT by Duplex Ultrasound
  4. Peripheral arterial disease (ABPI < 0.8), varicose veins or lower limb ulceration or ischemia.
  5. Significant varicose veins, phlebitis or lower limb ulceration or ischemia. CEAP Grade 4-6. See Appendix 2
  6. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement).
  7. Recent trauma to lower limb.
  8. Chronic Obesity (BMI Index >40kg/m2).
  9. Pregnancy.
  10. Significant history of following diseases I. Cardiovascular: Recent MI (< 6 months) II. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare Metal Stent (BMS) and < 12 months for Drug Eluding Stent (DES) III. Moderate to severe CCF, uncontrolled AF IV. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies V. Significant dermatological conditions affecting lower limbs resulting in broken or inflamed skin particularly at the site where the device is to be fitted.

    VI. Clinically significant haematological conditions i.e. coagulation disorders, sickle cell disease VII. Psychiatric disorders

  11. On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin
  12. Long term steroid with dermatological changes
  13. A pulse rate of less than 40 beats/minute
  14. A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg.
  15. Any significant illness during the four (4) weeks preceding the hip replacement surgery.
  16. Participation in any clinical study during the eight (8) weeks preceding the screening period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01935414

Contact: Matthew Womack, PhD +44(0) 7456427910 matthew.womack@firstkindmedical.com

United Kingdom
BMI The Harbour Hospital Recruiting
Poole, Dorset, United Kingdom, BH15 2BH
Sponsors and Collaborators
Firstkind Ltd

Additional Information:
Responsible Party: Firstkind Ltd
ClinicalTrials.gov Identifier: NCT01935414     History of Changes
Other Study ID Numbers: FKD-TEDS-001
First Posted: September 5, 2013    Key Record Dates
Last Update Posted: February 7, 2018
Last Verified: February 2018

Additional relevant MeSH terms:
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases